Drug development global

To extract the conformational properties of the molecule that is being studied, the conformational ensemble that was sampled and optimized must be analyzed. The analysis may focus on global properties, attempting to characterize features such as overall flexibility or to identify common trends in the conformation set. Alternatively, it may be used to identify a smaller subset of characteristic low energy conformations, which may be used to direct future drug development efforts. It should be stressed that the different conformational analysis tools can be applied to any collection of molecular conformations. These... 

Innovation in the Pharmaceutical Industry Globalization and New Ways of Drug Development. Berlin Springer, 2000. 

In order to expedite and optimise drug development, clinical trials are now conducted in different parts of the world. Recognising that drug development is a global process and in order that the data from one ethnic group can... 

Like all incentive mechanisms, contract R D has strengths as well as weaknesses. 1 argue below that the benefits outweigh drawbacks for preclinical and human trials. These programs reportedly account for three-quarters of all drug development costs (Global Alliance 2001). 

Peter van Brummelen, MD, PhD Emeritus Professor of Clinical Pharmacology, University of Basel, Pounder and Director of Van Brummelen Global Drug Development Consultancy BV, C. vanRennes-laan 19,1217 CW Hilversum, The Netherlands... 

Major customers for CRO services are the large global pharma (ceutical) companies. Half a dozen big pharma s (Pfizer, Glaxo SmithKline, Sanofi-Aventis, AstraZeneca, Johnson Johnson, and Merck) alone absorb an estimated 30% of all CRO spending. As for CMOs and also for CROs, biotech startup companies with their dichotomy between ambitious drug development programs and limited resources are the second most promising prospects after big pharma (see Section 12.3). 

Huang S-M, Temple R Is this the drug or dose for you Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008 84 287 or http //www.fda.gov/cder/genomics/publications.htm... 

AMC thus offers a way to make development of vaccines profitable, but is a pull mechanism since the sponsor pays only if the product meets the technical requirements and sells lots of units. Thus, the incentives are made similar to those of drugs for global diseases, in which innovators receive healthy profits only if their drug is approved and is purchased at a high price by many consumers. In addition, the sponsor has to make disbursements only if vaccine development leads to a product that consumers value it bears no unwanted risks. 

---